An Infection with Both Hepatitis B and C Viruses is Surprisingly Common; CBCD Reviews the Evidence

“Infected with the hepatitis B or C viruses (HNV or HCV)? The CBCD recommends taking Novirin or Gene-Eden-VIR.” – Greg Bennett, CBCD

Some doctors believe that up to 30% of those infected with hepatitis C (HCV) are also infected with hepatitis B (HBV). (1) However, numbers of those infected with both viruses may actually be higher. One study suggested that “the worldwide prevalence of HBV/HCV coinfection is unknown and might be underestimated with the phenomenon of silent (occult) HBV infection.” (2) Treatment of individuals with both HBV and HCV is extremely difficult and options are limited. “No standard recommendations exist for treatment of HBV/HCV co-infection, and therefore treatment must be individualized based on patient variables such as hepatitis blood test results and DNA or RNA levels, patient’s prior exposure to antiviral treatment, and the presence of other similarly transmitted viruses such as hepatitis D virus and human immunodeficiency virus (HIV).” (1) Moreover, when a person is infected with both HBV and HCV, the viruses behave in a different manner than when an individual is only infected with one strain. In addition, patients with both strains of hepatitis get sicker and have higher rates of cancer. “The virological patterns in coinfection cases are widely divergent and have dynamic profiles over time. As compared with monoinfected patients, HBV/HCV coinfected persons tend to have more severe liver injury, a higher probability of liver cirrhosis and hepatic decompensation, and a higher incidence of hepatocellular carcinoma.” (1)

Click to learn more about HCV symptoms.

The CBCD therefore recommends that individuals infected with HCV take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against the hepatitis viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected (hepatitis viruses) … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR.” (3) The study authors also wrote that “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (3)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

“The World Health Organization estimated that more than 350 million and 170 million people are chronic carriers of HBV and HCV, respectively. Because of their shared modes of transmission, coinfection with HBV and HCV is a fairly frequent occurrence.” (2)  Most of these people do not know they are infected. Even if an individual is concerned that he or she may be infected, they must be tested. “Because the clinical characteristics are similar for all types of acute viral hepatitis, the specific viral cause of illness cannot be determined solely on the basis of signs, symptoms, history, or current risk factors, but must be verified by specific serologic testing.” (4)

What treatments are available against the HCV virus?

Until recently, “the combination of a pegylated interferon (IFN)-α and ribavirin (was) the standard treatment for chronic HCV infections. This combination is effective in about 80% of the individuals infected with the HCV genotype 2 or 3, and in about 40% – 50% in those infected with genotype 1 or 4. Lately, two new drugs were approved, telaprevir and boceprevir, with better results. However, the combinations of pegylated interferon (IFN)-α and ribavirin and telaprevir or boceprevir are associated with additional side effects, increased costs, and more complex treatment strategies.” (3) Now, there is also Sovaldi, a recent FDA approved drug, which has proven very effective against HCV infection. However, the New York Times reports that the drug’s price tag is “$1,000 a pill and $84,000 total for a typical patient.” (4)

The CBCD reminds the public that there are also two natural, affordable HCV remedies. Those products are Novirin and Gene-Eden-VIR.

Click to learn more about Novirin and hepatitis C  and Gene-Eden-VIR and hepatitis C.

References:

(1)   Hepatitis B Foundation – What is HBV/HCV Co-infection?

(2)   Chi-Jen Chu, Shou-Dong Lee “Hepatitis B Virus/Hepatitis C Virus Coinfection: Epidemiology, Clinical Features, Viral Interactions and Treatment” J Gastroenterol Hepatol. 2008;23(4):512-520.

(3)   Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published September 2013.

(4) CDC.gov – Hepatitis C Information for Health Professionals

About CBCD

The Center for the Biology of Chronic Disease (https://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c) 3 of the IRS tax code. The center’s mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases.

About CBCD

About CBCD

The Center for the Biology of Chronic Disease (https://www.cbcd.net) is a not-for-profit tax-exempt organization under section 501(c) 3 of the IRS tax code. The center’s mission is to advance the research on the biology of chronic disease and to accelerate the discovery of a cure for these diseases. The CBCD first published Dr. Hanan Polansky’s highly acclaimed “Purple” book, entitled “Microcompetition with Foreign DNA and the Origin of Chronic Disease” in 2003. In this book, he explains how foreign DNA fragments can cause many major diseases. The book has been read by more than 5,000 scientists around the world, and has been reviewed in more than 20 leading scientific journals. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.